Abpro Holdings, Inc.

Abpro Holdings, Inc. is a biotechnology company focused on novel antibody constructs for immuno-oncology and ophthalmology. Its platforms include DiversImmune, a discovery platform that generates a diverse collection of proprietary antibodies against clinically validated and novel targets, and MultiMab, an engineering platform that combines antibody building blocks in different combinations and orientations to create full-length multi-specific antibody constructs. The company's lead product candidates include ABP-102, a next-generation immuno-oncology TetraBi antibody targeting HER2 and CD3 for HER2+ solid tumors, including breast and gastric cancers, and ABP-201, a TetraBi antibody that simultaneously inhibits VEGF and ANG-2 for vascular eye diseases, including diabetic macular edema and wet age-related macular degeneration. It also develops ABP-110, a TetraBi antibody targeting GPC3 and CD3 for hepatocellular carcinoma, and ABP-150, a TetraBi antibody targeting claudin 18.2 and CD3 for gastric cancers. The company has strategic partnerships with Celltrion Inc. and Abpro Bio International, Inc. Abpro Holdings, Inc. was incorporated in 2004 and is headquartered in Woburn, Massachusetts.